CN103613513B - Milnacipran hydrochloride intermediate and its preparation method and application - Google Patents
Milnacipran hydrochloride intermediate and its preparation method and application Download PDFInfo
- Publication number
- CN103613513B CN103613513B CN201310659257.3A CN201310659257A CN103613513B CN 103613513 B CN103613513 B CN 103613513B CN 201310659257 A CN201310659257 A CN 201310659257A CN 103613513 B CN103613513 B CN 103613513B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- formula
- inert solvent
- milnacipran hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZVSCENGNXWPDPL-UHFFFAOYSA-N CC(C)(CO)c1ccccc1 Chemical compound CC(C)(CO)c1ccccc1 ZVSCENGNXWPDPL-UHFFFAOYSA-N 0.000 description 1
- VJPWZKZAKJXDBR-UHFFFAOYSA-N CC(C)C(C(O)O)c1ccccc1 Chemical compound CC(C)C(C(O)O)c1ccccc1 VJPWZKZAKJXDBR-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to the synthetic method technical field of milnacipran hydrochloride.The present invention utilizes existing compound to generate new compound V through five step reactions, then the rear salify that reduced by compound V obtains milnacipran hydrochloride, often walk operation simple, mild condition, the yield of gained intermediate and final product is high, purity is high, provide a kind of economic, efficient milnacipran hydrochloride preparation method, be applicable to suitability for industrialized production.
Description
Technical field
The present invention relates to a kind of synthetic method technical field of milnacipran hydrochloride.
Background technology
Milnacipran hydrochloride researches and develops by French PierreFabre company the oral selectivity serotonin of one and noradrenaline reuptake inhibitor (SNRI) promoted, be used for the treatment of major depressive disorder (Majordepressivedisorder) curative effect apparently higher than Desipramine and imipramine, and without anticholinergic effect, more safe and reliable, in French Initial Public Offering in 1997.ForestLaboratoriesInc company of U.S. exploitation in 2009 is used for fibromyalgia syndrome (Fibromyalgia) U.S. FDA approval alive listing.
Milnacipran hydrochloride chemistry is by name: 2-(aminomethyl)-N, N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride, has following structure:
Patent EP0200638 discloses a kind of synthetic route of synthetic hydrochloric acid Midalcipran the earliest, and this synthetic method the first step temperature of reaction is high, and yield is low, and cause total recovery very low, concrete synthetic route is as follows:
Patent CN101107228 (SUMITOMO CHEMICAL KCC) discloses a kind of improvement synthetic route of synthetic hydrochloric acid Midalcipran, and concrete synthetic route is as follows:
This synthetic method the first step employs sodium methylate, and in reaction, cyclocomplex open loop generates a certain proportion of methyl esters, affects yield; Second step is introduced amino by phthalic acid imide, neither very economical.
Summary of the invention
Object of the present invention is just to provide the new intermediate of several synthetic hydrochloric acid Midalcipran, and what utilize this new intermediate compound energy economical and efficient prepares milnacipran hydrochloride.
Another object of the present invention is to provide the preparation method of above-mentioned new intermediate compound.
A further object of the invention is to provide above-mentioned new intermediate and is preparing the application in milnacipran hydrochloride.
For reaching above-mentioned purpose, the technical scheme that the present invention takes is as follows:
As shown in the formula compound V:
The preparation method of compound V, comprises the steps:
(1) type I compound reacts production II compound with thionyl chloride in methyl alcohol or ethanol
(2) formula II compound and sodium azide production III compound in inert solvent
(3) formula III compound and mineral alkali are hydrolyzed production IV compound in inert solvent
(4) IV compounds and diethylamine, in inert solvent, react production V compound under the effect of auxiliary reagent
The preparation method of above-claimed cpd V, wherein
Step (1) temperature of reaction is-10 ~ 80 DEG C, its preferably 0 ~ 70 DEG C;
In step (2), the ratio of sodium azide and formula II compound molar weight is 0.9 ~ 1.5: 1, preferably 1.0: 1; Temperature of reaction is 20 ~ 100 DEG C, most preferably 80 DEG C; Described inert solvent is selected from dimethyl formamide, toluene, acetonitrile, tetrahydrofuran (THF), N,N-DIMETHYLACETAMIDE etc., preferred dimethyl formamide;
In step (3), described mineral alkali is selected from sodium hydroxide, Strong oxdiative potassium, lithium hydroxide etc., preferred sodium hydroxide;
In step (3), the ratio of inorganic strong alkali and formula III compound molar weight is 0.9 ~ 3: 1, preferably 1.5 ~ 2.0: 1;
In step (3), described inert solvent is toluene, tetrahydrofuran (THF), methyl alcohol, ethanol etc., the mixture of one or more in preferred toluene or methyl alcohol;
In step (4), described inert solvent is selected from methylene dichloride, toluene, acetonitrile, tetrahydrofuran (THF), dimethyl formamide etc., preferred methylene dichloride; Described auxiliary reagent is DCC, trimethyl-acetyl chloride, methyl-chloroformate, Vinyl chloroformate, isobutylchloroformate, trimethyl-acetyl chloride etc., preferred DCC.
As shown in the formula compounds Ⅳ
Compounds Ⅳ is the midbody compound of compound V, and its preparation method is with step (1)-(3) in above-claimed cpd V preparation method.Compound III is the midbody compound of compounds Ⅳ, and its preparation method is with step (1)-(2) in above-claimed cpd V preparation method.Compound ii is the midbody compound of compound III, and its preparation method is with the step (1) in above-claimed cpd V preparation method.
Utilize compound V to prepare the method for milnacipran hydrochloride, the method is obtained by salify after reductive agent reduction in inert solvent:
Described reductive agent is: Pd/C-H
2, reductibility zinc powder, reductibility iron powder, triphenylphosphine, lithium aluminum hydride etc., preferred Pd/C-H
2.
From initial existing raw materials of compound I to milnacipran hydrochloride, its whole reaction scheme is as follows:
Beneficial effect of the present invention:
The present invention utilizes existing chemical compounds I through five step reacting generating compounds V, then the rear salify that reduced by compound V obtains milnacipran hydrochloride, often walk operation simple, mild condition, the yield of gained intermediate and final product is high, purity is high, provide a kind of economic, efficient milnacipran hydrochloride preparation method, be applicable to suitability for industrialized production.
Illustrate content of the present invention further below in conjunction with embodiment, these embodiments are not the restrictions to the scope of the invention and spirit.
figure of description
Fig. 1 is the HPLC collection of illustrative plates of the formula V compound that embodiment 4 obtains, and wherein in collection of illustrative plates, appearance time 16.111 place is formula V compound.
Fig. 2 is the nuclear magnetic spectrum of the formula V compound that embodiment 4 obtains.
Fig. 3 is the mass spectrum of the formula V compound that embodiment 4 obtains.
The present invention's laboratory apparatus used: Shimadzu-LC-20AD high performance liquid chromatography, VarianINOVA-400 nuclear magnetic resonance spectrometer, WatersQ-Tofmicro mass spectrograph, synthesis instrument are laboratory and commonly use conventional instrument.
Embodiment
Embodiment 1-3: the synthesis of formula II compound
(A) be dissolved in 500ml methyl alcohol by 100 grams of type I compound, then slowly drip 137g thionyl chloride, dropwise, room temperature reaction 10 hours, after TLC monitoring reacts completely, filter, filter cake is decompression drying at 40 DEG C.Obtain product 122g, yield 94.5%.
1HNMR(400MHz,CDCl
3):δ7.374-7.277(m,5H),3.685(s,3H),3.645-3.589(m,2H),1.891-1.875(m,1H),1.780-1.760(m,1H),1.493-1.467(m,1H)
(B) be dissolved in 500ml methyl alcohol by 100 grams of type I compound, then slowly drip 137g thionyl chloride, dropwise ,-5-5 DEG C is reacted 15 hours, and after TLC monitoring reacts completely, filter, filter cake is decompression drying at 40 DEG C.Obtain product 120g, yield 93%.
(C) be dissolved in 500ml methyl alcohol by 100 grams of type I compound, then slowly drip 137g thionyl chloride, dropwise, 70 DEG C are reacted 5 hours, and after TLC monitoring reacts completely, filter, filter cake is decompression drying at 40 DEG C.Obtain product 115g, yield 89%.
Embodiment 4-5: the synthesis of formula III compound
(A) II compound 100g and sodium azide 30g is joined in 500ml toluene, react 12 hours at 80 DEG C.After TLC monitoring reacts completely, cool to room temperature, adds 200ml water, and extraction separatory, organic layer evaporate to dryness obtains white solid.Filter, filter cake is decompression drying at 40 DEG C.Obtain product 91g, yield 88%.
(B) II compound 100g and sodium azide 30g is joined in 200ml dimethyl formamide, react 7 hours at 80 DEG C.After TLC monitoring reacts completely, cool to room temperature, pours in 200ml frozen water, separates out solid.Filter, filter cake is decompression drying at 40 DEG C.Obtain product 100g, yield 98%.
1HNMR(400MHz,CDCl
3):δ7.370-7.276(m,5H),3.663(s,3H),3.640-3.587(m,2H),1.877-1.862(m,1H),1.730-1.700(m,1H),1.459-1.424(m,1H)
Embodiment 6: the synthesis of formula IV compound
100 grams of formula III compounds are joined in (toluene 400ml, methyl alcohol 50ml, 20%NaOH105ml) mixing solutions, react 6 hours at 80 DEG C.After TLC monitoring reacts completely, cool to room temperature, separatory, water layer 6N hydrochloric acid furnishing slightly acidic, separates out solid.Filter, filter cake is decompression drying at 40 DEG C.Obtain product 90g, yield 95.6%.(fusing point: 95.1-95.7 DEG C)
1hNMR (400MHz, CDCl
3): δ 7.395-7.262 (m, 5H), 3.737-3.605 (m, 2H), 1.997-1.918 (m, 1H), 1.756-1.727 (m, 1H), 1.566-1.532 (m, 1H)
Embodiment 7-8: the synthesis of formula V compound
(A) in 50ml methylene dichloride, add formula IV compound 10g, diethylamine 6.7g and DCC10g, stirring at room temperature reacts 12 hours, filters, and filtrate is washed with saturated ammonium chloride, washed, anhydrous sodium sulfate drying.Filtration, evaporate to dryness obtain product 11.6g, yield 93%.See Figure of description 1, accompanying drawing 2, accompanying drawing 3
1HNMR(400MHz,CDCl
3):δ7.296-7.169(m,5H),3.550-3.440(m,2H),3.380-3.345(m,2H),2.226-3.070(m,2H),1.962-1.922(m,1H),1.552-1.524(m,1H),1.246-1.155(m,1H),1.134-1.074(m,3H),0.575-0.540(m,3H)
(B) in 250ml there-necked flask, formula IV compound 10g, methylene dichloride 100ml and triethylamine 5.6g is added, and at room temperature stir 5 minutes, slowly be added dropwise to trimethyl-acetyl chloride 6.4g, diethylamine 7g is added after detecting mixed anhydride and being fully formed, and reflux 7 hours, be cooled to room temperature, add water 50ml, extracting and demixing, organic layer evaporate to dryness obtains product 10g, yield 80%.
Embodiment 9: the synthesis of milnacipran hydrochloride
Be dissolved in 50ml methyl alcohol by formula V compound 11g, add 10%Pd/C1g, under hydrogen pressure 0.5MPa, catalytic hydrogenation reaction 2 hours, filters, adds hydrochloric acid 3.7ml in filtrate.Remove methyl alcohol under reduced pressure, add the making beating of 30ml ethyl acetate, filter and obtain product 10.6g, yield 95%.
1HNMR(400MHz,d
6-DMSO):δ7.442-7.350(m,5H),3.561-3.523(m,1H),3.412-3.377(m,1H),3.381-3.362(m,2H),3.161-3.143(m,2H),1.861-1.856(m,1H),1.796-1.784(m,1H),1.528-1.512(m,1H),1.159-1.140(m,3H),0.829-0.802(m,3H)。
Claims (5)
1. the preparation method of compound V, comprises the steps:
(1) type I compound reacts production II compound with thionyl chloride in methyl alcohol or ethanol
(2) formula II compound and sodium azide production III compound in inert solvent
Described inert solvent is selected from dimethyl formamide, toluene, acetonitrile, tetrahydrofuran (THF) and N,N-DIMETHYLACETAMIDE;
(3) formula III compound and mineral alkali are hydrolyzed production IV compound in inert solvent
Described inert solvent is toluene, tetrahydrofuran (THF), methyl alcohol and ethanol;
(4) IV compounds and diethylamine, in inert solvent, react production V compound under the effect of auxiliary reagent
Described inert solvent is selected from methylene dichloride, toluene, acetonitrile, tetrahydrofuran (THF) and dimethyl formamide; Described auxiliary reagent is DCC, methyl-chloroformate, Vinyl chloroformate, trimethyl-acetyl chloride or isobutylchloroformate.
2. the preparation method of compound V as claimed in claim 1, is characterized in that: the ratio of step (2) sodium azide and formula II compound molar weight is 0.9 ~ 1.5: 1.
3. the preparation method of compound V as claimed in claim 1, is characterized in that: the ratio of step (2) sodium azide and formula II compound molar weight is 1: 1.
4. the preparation method of compound V as claimed in claim 1, is characterized in that: the ratio of step (3) mineral alkali and formula III compound molar weight is 0.9 ~ 3: 1.
5. as shown in the formula compounds Ⅳ
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310659257.3A CN103613513B (en) | 2013-12-09 | 2013-12-09 | Milnacipran hydrochloride intermediate and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310659257.3A CN103613513B (en) | 2013-12-09 | 2013-12-09 | Milnacipran hydrochloride intermediate and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103613513A CN103613513A (en) | 2014-03-05 |
| CN103613513B true CN103613513B (en) | 2016-01-20 |
Family
ID=50164244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310659257.3A Active CN103613513B (en) | 2013-12-09 | 2013-12-09 | Milnacipran hydrochloride intermediate and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103613513B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108205043B (en) * | 2016-12-19 | 2020-05-19 | 成都弘达药业有限公司 | Detection method of levomilnacipran intermediate related substance |
| CN112759542B (en) * | 2019-11-04 | 2022-04-01 | 上海现代制药股份有限公司 | Drug intermediate, preparation and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2508033A1 (en) * | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | ARYL-1 AMINOMETHYL-2 CYCLOPROPANES CARBOXYLATES (Z), THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF VARIOUS ALGAE |
| FR2581059B1 (en) * | 1985-04-25 | 1988-04-22 | Pf Medicament | PROCESS FOR THE PREPARATION OF PHENYL-1 HYDROCHLORIDE DIETHYL AMINO CARBONYL-1 AMINOMETHYL-2 CYCLOPROPANE (Z) |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| JP4418717B2 (en) * | 2004-06-24 | 2010-02-24 | 住友化学株式会社 | Process for producing (Z) -1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride |
| JP4828863B2 (en) * | 2005-01-28 | 2011-11-30 | 住友化学株式会社 | Process for producing (Z) -1-phenyl-1- (N, N-diethylaminocarbonyl) -2-phthalimidomethylcyclopropane |
-
2013
- 2013-12-09 CN CN201310659257.3A patent/CN103613513B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103613513A (en) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101967145B (en) | Method for preparing antithrombotic medicament apixaban | |
| EP1930315A1 (en) | Process for production of mono-substituted alkylated compound using aldimine or derivative thereof | |
| US10927095B2 (en) | Processes for the preparation of Niraparib and intermediates thereof | |
| CN104130188B (en) | The preparation method of 8-chloro-1-methyl-2,3,4,5-tetrahydrochysene-1H-3-benzazepine | |
| CN104177331B (en) | The preparation method of bilastine | |
| CN102911160B (en) | Method for preparing and purifying dabigatran etexilate intermediate | |
| CN103613513B (en) | Milnacipran hydrochloride intermediate and its preparation method and application | |
| CN103601652A (en) | Preparation method of milnacipran hydrochloride | |
| CN112851646A (en) | Preparation method of Tegolrazan | |
| CN103601645A (en) | Preparation method of 1-(phenethylamino) propane-2-alcoholic compounds or salts thereof | |
| CA2980071A1 (en) | Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | |
| CN107118215B (en) | A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate | |
| CN111100128A (en) | Synthetic method of Ribocini intermediate product and intermediate compound thereof | |
| CN102964307B (en) | Dabigatran etexilate related substance and preparation method thereof | |
| CN103012408A (en) | Synthesis method of epinastine | |
| CN103980120A (en) | Synthesis method of D,L-danshensu isopropyl ester | |
| CN107935866B (en) | Preparation method of dapoxetine hydrochloride impurity | |
| WO2014068333A2 (en) | New process | |
| CN103288708B (en) | The preparation method of 1- aryl -2- indolinone derivative | |
| CN104774183B (en) | A kind of auspicious relax of formoxyl cuts down the preparation method of spit of fland calcium intermediate | |
| CN105985316A (en) | Preparation method for trelagliptin and salt thereof | |
| CN101137646A (en) | Synthesis of ccr5 antagonists | |
| CN102731408A (en) | Azilsartan intermediate and preparation method thereof | |
| CN102807516A (en) | Intermediate in amisulpride and method for preparing amisulpride by using intermediate | |
| JP7454498B2 (en) | Method for producing salicylamide acetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140305 Assignee: SINOPHARM WEIQIDA PHARMACEUTICAL CO.,LTD. Assignor: SHANGHAI SHYNDEC PHARMACEUTICAL Co.,Ltd. Contract record no.: X2022310000103 Denomination of invention: Milnacipran hydrochloride intermediate and its preparation method and application Granted publication date: 20160120 License type: Common License Record date: 20220831 |
|
| EE01 | Entry into force of recordation of patent licensing contract |